Aetna modified CPB 0422 governing vitiligo treatment coverage, effective September 26, 2025. Here's what billing teams need to act on now.
Aetna, a CVS Health company, updated its vitiligo coverage policy under CPB 0422 in the Aetna clinical policy bulletin system. The revision adds topical ruxolitinib (Opzelura) as an accepted step-therapy option before phototherapy — meaning its failure qualifies a member for light-based treatments like PUVA and NB-UVB. This directly affects claims billed under CPT 96900, 96912, 96913, and 96999 for excimer laser and phototherapy services.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna |
| Policy | Vitiligo — CPB 0422 |
| Policy Code | CPB 0422 |
| Change Type | Modified |
| Effective Date | September 26, 2025 |
| Impact Level | Medium |
| Specialties Affected | Dermatology, Phototherapy Centers |
| Key Action | Update documentation to include ruxolitinib (Opzelura) trial history as an accepted step-therapy qualifier before billing CPT 96900, 96912, 96913, or 96999. Check with Aetna directly for prior authorization requirements, as the source policy does not specify PA obligations. |
Aetna Vitiligo Coverage Criteria and Medical Necessity Requirements 2025
CPB 0422 now has three qualifying pathways for phototherapy. Based on the addition of ruxolitinib as a qualifying pathway, prior policy versions required failure of tacrolimus or corticosteroids — verify against the previous version of CPB 0422 before stating this as fact in PA submissions. As of September 26, 2025, failure of topical ruxolitinib (Opzelura) also qualifies.
Aetna now includes topical ruxolitinib (Opzelura) as an accepted step-therapy option before phototherapy — meaning its failure qualifies a member for light-based treatment. If your patients have tried Opzelura and failed, document that failure explicitly in your records.
The three qualifying pathways are:
| # | Covered Indication |
|---|---|
| 1 | Inadequate response to topical tacrolimus; or |
| 2 | Inadequate response to topical and systemic corticosteroids; or |
| 3 | Inadequate response to topical ruxolitinib (Opzelura) |
Meeting any one of these qualifies a member for photochemotherapy (PUVA), excimer laser, or narrow-band UVB therapy. You don't need all three. One failed trial is enough.
Continued Therapy Requires a Clinical Benchmark
Aetna's coverage policy draws a hard line at six months. Continued PUVA (CPT 96912, 96913) or NB-UVB (CPT 96900) is not medically necessary unless the patient shows significant follicular pigmentation after six months of therapy. Aetna defines the treatment intensity as eight to ten treatments per month.
This is the clause that generates the most claim denial risk for phototherapy practices. If a patient has been receiving light treatments for six months without documented follicular repigmentation, continued treatment will not meet medical necessity under this policy. Chart that clinical benchmark at every visit. Your documentation needs to show it — not just assert it.
Aetna Vitiligo Exclusions and Non-Covered Indications
Several treatments in the CPB 0422 code list are explicitly not covered for vitiligo. Aetna does not cover surgical grafting options — specifically epidermal autografts billed under CPT 15110, 15111, 15115, and 15116. Split-thickness autografts (CPT 15100, 15101) also appear in the non-covered or experimental groupings.
Tattooing procedures (CPT 11920, 11921, 11922) used for skin color correction are not covered for vitiligo indications. Platelet-rich plasma injection (CPT 0232T) and PRP by unit (HCPCS P9020) are excluded. Acupuncture codes 97810 and 97811 appear in the experimental/investigational grouping.
Biologics that work for other dermatologic conditions — adalimumab (HCPCS J0139), etanercept (J1438), infliximab (J1745), and their biosimilars — are not covered for vitiligo under this policy. Neither are CAR-T therapy codes (38225–38228), aldesleukin (J9015), or capecitabine (J8520, J8521, J8522).
The real issue here is that some of these codes might appear in a patient's chart for a comorbid condition. Make sure your vitiligo claims don't inadvertently include non-covered codes. If a patient has both vitiligo and a condition requiring infliximab, bill those claims separately and clearly. Mixed claims create audit exposure.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| PUVA after failed topical tacrolimus, topical/systemic corticosteroids, or ruxolitinib | Covered | CPT 96912, 96913 | Must document failed first-line therapy; check with Aetna directly for PA requirements |
| NB-UVB after failed first-line therapy | Covered | CPT 96900 | Same step-therapy documentation applies |
| Excimer laser after failed first-line therapy | Covered | CPT 96999 | Unlisted code — use with clear documentation of excimer laser service |
| Continued PUVA or NB-UVB beyond 6 months | Covered with criteria | CPT 96900, 96912, 96913 | Requires documented significant follicular pigmentation; 8–10 tx/month intensity |
| Topical/systemic corticosteroids (injectable) | Covered | HCPCS J0702, J1020, J1030, J1040, J1094, J1100, J1700, J1710, J1720, J2650, J2920, J2930, J3301, J3302, J3303, J7509, J7510, J7512, J8540 | Standard step-therapy; must appear in trial history |
| Home UV equipment | Covered with criteria | HCPCS E0691–E0694, A4633 | Home NB-UVB after clinical criteria met |
| Epidermal autograft | Not Covered | CPT 15110, 15111, 15115, 15116 | Not covered for vitiligo indications |
| Split-thickness autograft | Not Covered / Experimental | CPT 15100, 15101 | Same exclusion applies |
| Tattooing for color correction | Not Covered | CPT 11920, 11921, 11922 | Cosmetic correction not covered |
| PRP injection | Not Covered | CPT 0232T, HCPCS P9020 | Excluded for vitiligo |
| Biologics (TNF-alpha inhibitors, rituximab) | Not Covered | J0139, J1438, J1745, J9312, Q5103–Q5145 | Not covered for vitiligo indication |
| CAR-T therapy | Not Covered | CPT 38225–38228 | Not covered for vitiligo |
| Acupuncture | Not Covered | CPT 97810, 97811 | Excluded |
| Aldesleukin, capecitabine, oprelvekin | Not Covered | J9015, J8520, J8521, J8522, J2355 | Excluded |
Aetna Vitiligo Billing Guidelines and Action Items 2025
| # | Action Item |
|---|---|
| 1 | Update your step-therapy documentation templates before the September 26, 2025 effective date, or immediately if that date has passed. Add a field for ruxolitinib (Opzelura) trial documentation. If your templates only ask about tacrolimus and corticosteroids, they're already out of date. |
| 2 | Document failed first-line therapy clearly in the medical record. "Patient did not respond to Opzelura" is not enough. Document the clinical outcome clearly in the medical record to support the coverage criteria. |
| 3 | Set a 6-month documentation checkpoint for every active phototherapy patient. At that point, you need clinical evidence of significant follicular pigmentation. Build this checkpoint into your treatment workflow now — not after a denial. For vitiligo billing on CPT 96900, 96912, or 96913, this is your biggest claim denial risk. |
| 4 | Verify treatment intensity matches the policy standard. Aetna specifies eight to ten treatments per month for continued PUVA or NB-UVB therapy to meet the continuation criteria. If your patient is getting four treatments a month, that's a problem. The frequency needs to be in the chart, not just implied. |
| 5 | Confirm diagnosis codes on all vitiligo claims use ICD-10 L80. That's the only covered vitiligo diagnosis code in CPB 0422. ICD-10 M30.0–M35.9 (polyarteritis nodosa and related conditions) also appears in the policy's code list — likely for autoimmune comorbidity documentation — but your primary claim should anchor to L80 for vitiligo-specific services. |
| 6 | Audit any phototherapy claims that include non-covered CPT codes. If your encounter form bundles surgical grafting (15100, 15101, 15110–15116) or biologics (J0139, J1438, J1745) for vitiligo patients, those lines will deny. Split those services out by indication and confirm separate coverage criteria. |
| 7 | For home UV therapy equipment, check with Aetna directly for prior authorization requirements before billing E0691–E0694. The source policy does not specify PA obligations for home equipment. Confirm whether the home equipment authorization pathway aligns with the clinical criteria for the treatment itself. |
If your practice has a high volume of vitiligo phototherapy cases or you're uncertain how the ruxolitinib step-therapy addition applies to your patient mix, loop in your compliance officer before submitting requests under the updated policy. The step-therapy documentation burden here is real.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Vitiligo Under CPB 0422
Covered CPT Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| 96900 | CPT | Actinotherapy (ultraviolet light) — Narrow-band UVB (NB-UVB) |
| 96912 | CPT | Photochemotherapy; psoralens and ultraviolet A (PUVA) |
| 96913 | CPT | Photochemotherapy (Goeckerman and/or PUVA) for severe photoresponsive dermatoses requiring at least 4 hours |
| 96999 | CPT | Unlisted special dermatological service or procedure [excimer laser — XTRAC, EX-308] |
Covered HCPCS Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| J0702 | HCPCS | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg |
| J1020 | HCPCS | Injection, methylprednisolone acetate, 20 mg |
| J1030 | HCPCS | Injection, methylprednisolone acetate, 40 mg |
| J1040 | HCPCS | Injection, methylprednisolone acetate, 80 mg |
| J1094 | HCPCS | Injection, dexamethasone acetate, 1 mg |
| J1100 | HCPCS | Injection, dexamethasone sodium phosphate, 1 mg |
| J1700 | HCPCS | Injection, hydrocortisone acetate, up to 25 mg |
| J1710 | HCPCS | Injection, hydrocortisone sodium phosphate, up to 50 mg |
| J1720 | HCPCS | Injection, hydrocortisone sodium succinate, up to 100 mg |
| J2650 | HCPCS | Injection, prednisolone acetate, up to 1 ml |
| J2920 | HCPCS | Injection, methylprednisolone sodium succinate, up to 40 mg |
| J2930 | HCPCS | Injection, methylprednisolone sodium succinate, up to 125 mg |
| J3301 | HCPCS | Injection, triamcinolone acetonide, per 10 mg |
| J3302 | HCPCS | Injection, triamcinolone diacetate, per 5 mg |
| J3303 | HCPCS | Injection, triamcinolone hexacetonide, per 5 mg |
| J7509 | HCPCS | Methylprednisolone, oral, per 4 mg |
| J7510 | HCPCS | Prednisolone, oral, per 5 mg |
| J7512 | HCPCS | Prednisone, immediate release or delayed release, oral, 1 mg |
| J8540 | HCPCS | Dexamethasone, oral, 0.25 mg |
| A4633 | HCPCS | Replacement bulb/lamp for ultraviolet light therapy system, each |
| E0691 | HCPCS | Ultraviolet light therapy system panel, treatment area up to 2 sq ft |
| E0692 | HCPCS | Ultraviolet light therapy system panel, four foot panel |
| E0693 | HCPCS | Ultraviolet light therapy system panel, six foot panel |
| E0694 | HCPCS | Ultraviolet multidirectional light therapy system, 6 foot cabinet |
Not Covered CPT Codes for Vitiligo Indications
| Code | Type | Description | Reason |
|---|---|---|---|
| 15110 | CPT | Epidermal autograft, trunk, arms, legs; first 100 sq cm or less | Not covered |
| 15111 | CPT | Epidermal autograft, trunk, arms, legs; each additional 100 sq cm | Not covered |
| 15115 | CPT | Epidermal autograft, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet | Not covered |
| 15116 | CPT | Epidermal autograft, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet; additional | Not covered |
| 84150 | CPT | Prostaglandin, each | Not covered |
| 86341 | CPT | Islet cell antibody | Not covered |
Experimental / Investigational CPT Codes
| Code | Type | Description | Reason |
|---|---|---|---|
| 0232T | CPT | Injection(s), platelet rich plasma, any site, including image guidance | Experimental/investigational |
| 11920 | CPT | Tattooing, intradermal introduction of insoluble opaque pigments, 6 sq cm or less | Not covered for vitiligo |
| 11921 | CPT | Tattooing, 6.1 to 20.0 sq cm | Not covered for vitiligo |
| 11922 | CPT | Tattooing, each additional 20.0 sq cm or part thereof | Not covered for vitiligo |
| 15100 | CPT | Split-thickness autograft, trunk, arms, legs; first 100 sq cm or less | Experimental/investigational |
| 15101 | CPT | Split-thickness autograft; each additional 100 sq cm | Experimental/investigational |
| 38225 | CPT | CAR-T therapy; harvesting of blood-derived T lymphocytes | Experimental/investigational |
| 38226 | CPT | CAR-T therapy; preparation of blood-derived T lymphocytes | Experimental/investigational |
| 38227 | CPT | CAR-T therapy; receipt and preparation of CAR-T cells | Experimental/investigational |
| 38228 | CPT | CAR-T therapy; CAR-T cell administration, autologous | Experimental/investigational |
| 76376 | CPT | 3D rendering with interpretation and reporting of CT, MRI, ultrasound | Experimental/investigational |
| 76377 | CPT | 3D rendering requiring image postprocessing on an independent workstation | Experimental/investigational |
| 81291 | CPT | MTHFR gene analysis | Experimental/investigational |
| 97810 | CPT | Acupuncture, without electrical stimulation, initial 15 minutes | Not covered for vitiligo |
| 97811 | CPT | Acupuncture, without electrical stimulation, each additional 15 minutes | Not covered for vitiligo |
Not Covered / Experimental HCPCS Codes
| Code | Type | Description | Reason |
|---|---|---|---|
| J0139 | HCPCS | Injection, adalimumab, 1 mg | Not covered for vitiligo |
| J0636 | HCPCS | Injection, calcitriol, 0.1 mcg | Not covered for vitiligo |
| J1438 | HCPCS | Injection, etanercept, 25 mg | Not covered for vitiligo |
| J1745 | HCPCS | Injection, infliximab, 10 mg | Not covered for vitiligo |
| J2501 | HCPCS | Injection, paricalcitol, 1 mcg | Not covered for vitiligo |
| J8522 | HCPCS | Capecitabine, oral, 50 mg | Not covered for vitiligo |
| J9312 | HCPCS | Injection, rituximab, 10 mg | Not covered for vitiligo |
| P9020 | HCPCS | Platelet rich plasma, each unit | Not covered for vitiligo |
| Q5103 | HCPCS | Injection, infliximab-dyyb (Inflectra) biosimilar, 10 mg | Not covered for vitiligo |
| Q5104 | HCPCS | Injection, infliximab-abda (Renflexis) biosimilar, 10 mg | Not covered for vitiligo |
| Q5109 | HCPCS | Injection, infliximab-qbtx (Ixifi) biosimilar, 10 mg | Not covered for vitiligo |
| Q5140 | HCPCS | Injection, adalimumab-fkjp biosimilar, 1 mg | Not covered for vitiligo |
| Q5141 | HCPCS | Injection, adalimumab-aaty biosimilar, 1 mg | Not covered for vitiligo |
| Q5142 | HCPCS | Injection, adalimumab-ryvk biosimilar, 1 mg | Not covered for vitiligo |
| Q5143 | HCPCS | Injection, adalimumab-adbm biosimilar, 1 mg | Not covered for vitiligo |
| Q5144 | HCPCS | Injection, adalimumab-aacf (Idacio) biosimilar, 1 mg | Not covered for vitiligo |
| Q5145 | HCPCS | Injection, adalimumab-afzb (Abrilada) biosimilar, 1 mg | Not covered for vitiligo |
| S0161 | HCPCS | Calcitriol, 0.25 mcg | Not covered for vitiligo |
| J2355 | HCPCS | Injection, oprelvekin, 5 mg | Not covered for vitiligo |
| J8520 | HCPCS | Capecitabine, oral, 150 mg | Not covered for vitiligo |
| J8521 | HCPCS | Capecitabine, oral, 500 mg | Not covered for vitiligo |
| J9015 | HCPCS | Injection, aldesleukin, per single use vial | Not covered for vitiligo |
Key ICD-10-CM Diagnosis Codes
| Code | Description |
|---|---|
| L80 | Vitiligo |
| M30.0–M35.9 | Polyarteritis nodosa and related conditions |
Get the Full Picture for CPT 96900
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.